Navigation Links
First Huntington's disease center established in Washington, D.C., area
Date:7/19/2012

WASHINGTON -- Georgetown University Medical Center in collaboration with MedStar Georgetown University Hospital announce the launch of the Huntington Disease Care, Education and Research Center. With support from the Griffin Foundation, the Huntington Disease Center is the first comprehensive, multidisciplinary center to focus on treatment, patient education and research of the disease in the Washington, D.C. area.

Huntington disease (HD) is a hereditary, progressively degenerative brain disorder for which there is no cure, and only one approved treatment for symptoms. HD causes involuntary body movements, cognitive decline, and a host of behavioral disturbances that slowly diminish the ability to walk, talk and reason. Treatment of a person with HD involves a skilled clinical team to make an accurate diagnosis and provide comprehensive care. About 30,000 people in the United States have HD and about 150,000 individuals carry a 50 percent risk of having inherited the fatal HD gene.

"Caring for those with Huntington disease and their families takes a comprehensive and tailored approach," explains MedStar Georgetown University Hospital President Richard Goldberg, MD. "MedStar Georgetown and Georgetown University Medical Center are assembling a team of specialized neurologists, psychiatrists, social workers and other specialists as a part of the new Huntington Disease Center. Up until now, people with HD have been underserved in the Washington, DC area. This Center changes that."

The joint endeavor will be lead by GUMC's Ira Shoulson, M.D., who will serve as interim director of the Center. Shoulson, a professor in the Department of Neurology, is a leading researcher in Huntington disease and founder of the Huntington Study Group, an international academic consortium of clinical researchers.

There will be two clinical co-directors of the Center representing the critical collaboration necessary of neurology and psychiatry in caring for patients and their families. They are Fahd Amjad, M.D., an assistant professor in the Department of Neurology and a member of MedStar GUH's Movement Disorders Program; and Thomas Cummings, M.D., an assistant professor in the Department of Psychiatry.

"Huntington disease is devastating for entire families emotionally, socially and economically," says Howard J. Federoff, M.D., Ph.D., executive vice president for health sciences at Georgetown University Medical Center (GUMC) and executive dean of Georgetown's School of Medicine. "Delivering comprehensive care, or cura personalis -- care of the whole person, is central to the mission of the new Center. It will also give considerable focus on research to discover new approaches to both treat the symptoms and slow the progression of the disease."

Recognizing the multidisciplinary, collaborative effort needed for a successful care and research program for Huntington disease, MedStar GUH and GUMC marked the launch of the Huntington Disease Center with an inaugural symposium that assembled some of the nation's leading experts in care, education and research of Huntington disease.

Through the funding of Huntington Disease Center, the Griffin Foundation hopes to assist in the creation of a model center for the care of Huntington disease patients that provides the clinical support, education and services desperately needed by families and caregivers in the Washington, D.C. area.

In addition to the MedStar GUH location, the Huntington Care, Education and Research Center plans to establish two community-based clinics in Virginia and Maryland to improve access and reduce travel time and inconvenience faced by those with Huntington disease.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Study Gives First Evidence That Adult Human Lungs Can Regrow
2. Hookah smoking increasingly common among first-year college women
3. Sohn Conference and Damon Runyon Cancer Research Foundations name first pediatric research fellows
4. Scientists first to see trafficking of immune cells in beating heart
5. First-of-its-kind approach nanomedicine design effectively targets cancer with decreased toxicity
6. First Is Viewed as Best When Making Quick Decisions
7. Heuer M.D. Research Announces CardiaShred™ - First Medical Doctor Formulated, Heart Healthy Weight Loss, Energy and Lean Muscle Building Supplement
8. Massage Industry Heavyweights Team Up for First-Ever Massage Documentary
9. Health interventions for clergy must counteract need to put others first
10. FDA Approves First New Weight-Loss Drug in More Than a Decade
11. Ecig Advanced Sponsors Lexington's First Annual Vaping Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: